Literature DB >> 27575587

Clinical development of MUSE cell treatment: The challenges.

Jan Stolk1.   

Abstract

Entities:  

Keywords:  Cellular heterogeneity; inflammation; repair; secretome; tissue destruction

Mesh：

Substances：

Year:  2016        PMID： 27575587      PMCID： PMC5176146          DOI： 10.1080/15384101.2016.1229014

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  6 in total

1.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

Authors:  Katarina Le Blanc; Ida Rasmusson; Berit Sundberg; Cecilia Götherström; Moustapha Hassan; Mehmet Uzunel; Olle Ringdén
Journal:  Lancet       Date:  2004-05-01       Impact factor: 79.321

2.  The secretome of MUSE cells contains factors that may play a role in regulation of stemness, apoptosis and immunomodulation.

Authors:  Nicola Alessio; Servet Özcan; Kazuki Tatsumi; Ayşegül Murat; Gianfranco Peluso; Mari Dezawa; Umberto Galderisi
Journal:  Cell Cycle       Date:  2016-07-27       Impact factor: 4.534

3.  Bone marrow stromal cells generate muscle cells and repair muscle degeneration.

Authors:  Mari Dezawa; Hiroto Ishikawa; Yutaka Itokazu; Tomoyuki Yoshihara; Mikio Hoshino; Shin-ichi Takeda; Chizuka Ide; Yo-ichi Nabeshima
Journal:  Science       Date:  2005-07-08       Impact factor: 47.728

4.  Unique multipotent cells in adult human mesenchymal cell populations.

Authors:  Yasumasa Kuroda; Masaaki Kitada; Shohei Wakao; Kouki Nishikawa; Yukihiro Tanimura; Hideki Makinoshima; Makoto Goda; Hideo Akashi; Ayumu Inutsuka; Akira Niwa; Taeko Shigemoto; Yoko Nabeshima; Tatsutoshi Nakahata; Yo-Ichi Nabeshima; Yoshinori Fujiyoshi; Mari Dezawa
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

5.  A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype.

Authors:  Ruth S Waterman; Suzanne L Tomchuck; Sarah L Henkle; Aline M Betancourt
Journal:  PLoS One       Date:  2010-04-26       Impact factor: 3.240

6.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.

Authors:  Katarina Le Blanc; Francesco Frassoni; Lynne Ball; Franco Locatelli; Helene Roelofs; Ian Lewis; Edoardo Lanino; Berit Sundberg; Maria Ester Bernardo; Mats Remberger; Giorgio Dini; R Maarten Egeler; Andrea Bacigalupo; Willem Fibbe; Olle Ringdén
Journal:  Lancet       Date:  2008-05-10       Impact factor: 79.321
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.